STOCKHOLM, August 27, 2010 /PRNewswire/ -- Athera Biotechnologies and Electra-Box Diagnostica, announced today that they have signed an agreement for distribution of "CVDefine" kit. CVDefine measures a new biomarker in blood, a specific anti-body, that has been linked to increased risk for cardiovascular disease. Athera Biotechnologies is part of the Karolinska Development portfolio.
Carina Schmidt, VD i Athera:
"This is an important step in the broader commercialization of CVDefine. Together with Electra-Box we will now be able to expand our contacs with leading clinial scientist in the cardiovascular field and increase the exposure of our trademark. We look forward to be able to work with the experienced Electra-Box team."
Peter Blom, responsible for clinical chemistry in Electra-Box Diagnostica: "We are very excited about the opportunities this agreement present. This will allow us to offer a new CVD biomarker to customers in Scandinavia. Since CVDefine(R) may add important and independent information in cardiovascular risk assessment; we believe there is a lot of interest from scientist in the field to generate further clinical research data".
High levels of IgM antibodies against phosphorylcholine (anti-PC) have
been shown to be cardio-protective. Low levels of anti-PC are known to be
involved in atherosclerosis development and increased risk for acute
cardiovascular events, like stroke and myocardial infarction. Athera is
investigating the possibilities to develop new immunological therapies to
prevent secondary cardiovascular events and to identify the patients who
benefit most from this treatment with CVDefine, and consequen
|SOURCE Athera Biotechnologies AB|
Copyright©2010 PR Newswire.
All rights reserved